Ranbaxy to get royalty for Cipro XR sales in US
Facebook Twitter google+ RSS Feed

Ranbaxy to get royalty for Cipro XR sales in US

Tuesday, 17 December 2002, 08:00 Hrs
Printer Print Email Email
NEW DELHI: India's pharma major Ranbaxy Laboratories Monday said it would be receiving royalty from Bayer for marketing its urinary tract infection drug Cipro XR (Ciprofloxacin extended release tablets), which has been cleared by the U.S. Food and Drug Administration.

Cipro XR, to be marketed in a dosage strength of 500 mg, is administered once a day for three days to treat uncomplicated urinary tract infections (UTIs).

Cipro XR releases the active ingredient from two layers. The first releases ciprofloxacin into the blood within hours. This is followed by a second extended release of the active ingredient to allow sustained levels over 24 hours.

Bayer had submitted the product for FDA approval for marketing in October 2002. It will begin shipping the products to U.S. pharmacies from January 2.
Source: IANS
Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Sr. Executive
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
Reena Khanna
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset